Coverage
-
January 31, 2022
Bristol-Myers Squibb subsidiary Celgene has settled litigation in the U.S. that sought to block Indian drugmaker Dr. Reddy's from marketing generic versions of its blockbuster cancer medication Pomalyst, according to documents that the two sides filed on Friday in New Jersey federal court.
1 other articles on this case.
View all »